Tocilizumab For GCA – EAP Approved

Funding for tocilizumab (Actemra) will be considered for the treatment of new onset or relapsed Giant Cell Arteritis (GCA) through the Exceptional Access Program (EAP) in adult patients meeting all the following criteria: […]

Read More…


OHIP+ Redesign Update

The MOHLTC has published an FAQ document that may be accessed via this link: FAQ OHIP+ […]

Read More…


Form For Prescription Drugs Previously Funded Through OHIP+ That Require Prior Authorization From a Private Insurer

On March 29, 2019 representatives from the ORA Board met with the MOHLTC to discuss the new OHIP+. The following information was shared by the Ministry: Form for prescription drugs previously funded through OHIP+ that […]

Read More…


Key Contact Numbers If Your Patients Are Having Challenges With the Changes to OHIP+

Representatives from the ORA Board recently met with the MOHLTC to discuss the changes to OHIP+ that are now in effect. The following key contact numbers were provided by the Ministry and may […]

Read More…


Imminent changes to OHIP+ will create access challenges for Ontario children who require medication

Daniel and Nathan are 8 year-old twin brothers with a rare and potentially lethal disease.  Prior to receiving a new treatment that blocks an overproduced chemical in their immune system, they experienced frequent […]

Read More…


Important Update for Temporary Facilitated Access Mechanism for Rheumatology and Changes to OHIP+

There is an important update on the Temporary Facilitated Access (TFA) mechanism for rheumatology, regarding the imminent changes on March 31, 2019. The ORA has been asked to pass along the attached letter […]

Read More…


Ontario eConsult Service

The Ontario Rheumatology Association is working on improving patient access to specialist rheumatologic care across the province. One of the ways that this could be improved is enhanced access to subspecialist rheumatologists for […]

Read More…


Drug Shortage Update – Methotrexate

There is a drug shortage update for Methotrexate. More information is available via this link: Drug Shortage MTX […]

Read More…


Ondansetron for Methotrexate-Induced Nausea/Vomiting

The ORA EAP Committee met with the MOHLTC last year and submitted a request to have ondansetron funded for pediatric patients with rheumatic diseases who are receiving weekly oral or subcutaneous methotrexate. It […]

Read More…


Updated Notice – Temporary Facilitated Access Mechanism

Please find the attached notice from the Executive Officer regarding an update to pharmacies about the claims submission process under the Temporary Facilitated Access Mechanism (TFA Rheumatology) using the Health Network System (HNS). […]

Read More…